Ir al contenido
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
Menú
  • About Us
    • Brand History
    • History of P4HB
  • What is GalaFLEX?
    • Instructions for Use
    • What is P4HB?
    • Properties
    • The Scaffold Collection
      • GalaFLEX®
      • GalaFLEX 3D TM
      • GalaFLEX 3DR TM
    • Information for your patient
  • Publications
  • Contact Us
    • Locations
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.

Publications

Evaluation of a fully absorbable poly-4-hydroxybutyrate/absorbable barrier composite mesh in a porcine model of ventral hernia repair

Jeffrey R. Scott, Corey R. Deeken, Robert G. Martindale, Michael J. Rosen


Surgical Endoscopy

September 2016, Volume 30, Issue 9, pp 3691–3701

Full article: https://www.ncbi.nlm.nih.gov/pubmed/27369286

 

Background

The objective of this study was to evaluate the mechanical and histological properties of a fully absorbable poly-4-hydroxybutyrate/absorbable barrier composite mesh (Phasix™ ST) compared to partially absorbable (Ventralight™ ST), fully absorbable (Phasix™), and biologically derived (Strattice™) meshes in a porcine model of ventral hernia repair.

 

Methods

Bilateral abdominal surgical defects were created in twenty-four Yucatan pigs, repaired with intraperitoneal (Phasix™ ST, Ventralight™ ST) or retromuscular (Phasix™, Strattice™) mesh, and evaluated at 12 and 24 weeks (n = 6 mesh/group/time point).

 

Results

Prior to implantation, Strattice™ demonstrated significantly higher (p < 0.001) strength (636.6 ± 192.1 N) compared to Ventralight™ ST (324.3 ± 37.1 N), Phasix™ ST (206.9 ± 11.3 N), and Phasix™ (200.6 ± 25.2 N). At 12 and 24 weeks, mesh/repair strength was significantly greater than NAW (p < 0.01 in all cases), and no significant changes in strength were observed for any meshes between 12 and 24 weeks (p > 0.05). Phasix™ mesh/repair strength was significantly greater than Strattice™ (p < 0.001) at 12 and 24 weeks, and Ventralight™ ST mesh/repair strength was significantly greater than Phasix™ ST mesh (p < 0.05) at 24 weeks. At 12 and 24 weeks, Phasix™ ST and Ventralight™ ST were associated with mild inflammation and minimal–mild fibrosis/neovascularization, with no significant differences between groups. At both time points, Phasix™ was associated with minimal–mild inflammation/fibrosis and mild neovascularization. Strattice™ was associated with minimal inflammation/fibrosis, with minimal neovascularization at 12 weeks, which increased to mild by 24 weeks. Strattice™ exhibited significantly less neovascularization than Phasix™ at 12 weeks and significantly greater inflammation at 24 weeks due to remodeling.

 

Conclusions

Phasix™ ST demonstrated mechanical and histological properties comparable to partially absorbable (Ventralight™ ST) and fully resorbable (Phasix™) meshes at 12 and 24 weeks in this model. Data also suggest that fully absorbable meshes with longer-term resorption profiles may provide improved mechanical and histological properties compared to biologically derived scaffolds.

 

Disclosures

This study was sponsored by C. R. Bard, Inc. (Davol), Warwick, RI. Drs. Robert Martindale, Corey Deeken, and Michael Rosen are paid consultants for, and Dr. Jeffrey R. Scott is an employee of C. R. Bard, Inc. (Davol).

  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
Menú
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact

See instructions for use here

+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev B
  • Terms of Use
  • Privacy Policy
Menú
  • Terms of Use
  • Privacy Policy
+ Show References
+ Show patents
Twitter Instagram Linkedin Facebook
Galatea Surgical© 2023. All Rights reserved 500075 Rev DB
  • Terms of Use
  • Privacy Policy
  • Terms of Use
  • Privacy Policy
Important Cookie Information – This message will only appear once. Galatea Surgical website uses cookies. By continuing to browse the site, you are agreeing to the use of cookies.
Read Privacy Policy ACCEPT
Manage consent

Privacy Overview

Read Privacy Policy

Necessary
Siempre activado
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
GUARDAR Y ACEPTAR
The information contained in this website is intended for International Health Care Professionals. Patients, please refer to your physician for information.
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact
  • Home
  • About Us
  • What is GalaFLEX?
  • Publications
  • Contact